"Inverse Vaccine" Shows Promise in Treating Multiple Autoimmune Diseases, Including MS
An "inverse vaccine" approach using ANK-700, which teaches the immune system not to attack specific targets, has shown promise in reducing disease activity in mouse models of multiple sclerosis (MS). The vaccine works by inducing immune tolerance, preventing the immune system from attacking the myelin sheath in the brain and spinal cord. ANK-700 is currently being tested in early clinical trials for MS treatment, with the potential to provide disease control without impairing the immune system's ability to defend against infections.